```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653rbm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09  ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS  4  OCT 03  MATHDI removed from STN
 NEWS  5  OCT 04  CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                  to core patent offices
 NEWS  6  OCT 06  STN AnaVist workshops to be held in North America
 NEWS  7  OCT 13  New CAS Information Use Policies Effective October 17, 2005
 NEWS  8  OCT 17  STN(R) AnaVist(TM), Version 1.01, allows the export/download
                  of CAplus documents for use in third-party analysis and
                  visualization tools
 NEWS  9  OCT 27  Free KWIC format extended in full-text databases
 NEWS 10  OCT 27  DIOGENES content streamlined
 NEWS 11  OCT 27  EPFULL enhanced with additional content
 NEWS 12  NOV 14  CA/CAplus - Expanded coverage of German academic research

 NEWS EXPRESS  NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:47:40 ON 21 NOV 2005

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
```

```
      AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
      BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
      CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 17:47:55 ON 21 NOV 2005

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=>
=> (alpha with facor with leader with sequence) and  (ADH2 with promoter) and
("interleukin" with "2" with sequences)
  13 FILES SEARCHED...
  15 FILES SEARCHED...
  21 FILES SEARCHED...
  27 FILES SEARCHED...
  34 FILES SEARCHED...
  48 FILES SEARCHED...
  54 FILES SEARCHED...
  64 FILES SEARCHED...
  72 FILES SEARCHED...

   0 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L1   QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)
        AND ("INTERLEUKIN" WITH "2" WITH SEQUENCES)

=> alpha and facor and leader and sequence and  and ADH2 with promoter and
("interleukin" with "2") and sequences
MISSING TERM 'AND  AND'
The search profile that was entered contains a logical
operator followed immediately by another operator.

=> (ADH2 with promoter) and ("interleukin" with "2" with sequences)
  15 FILES SEARCHED...
  27 FILES SEARCHED...
  34 FILES SEARCHED...
  39 FILES SEARCHED...
  54 FILES SEARCHED...
  66 FILES SEARCHED...

   0 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L2   QUE (ADH2 WITH PROMOTER) AND ("INTERLEUKIN" WITH "2" WITH SEQUENCES)

=> (alpha with facor with leader with sequence) and  (ADH2 with promoter)
  15 FILES SEARCHED...
  27 FILES SEARCHED...
  34 FILES SEARCHED...
  47 FILES SEARCHED...
  54 FILES SEARCHED...
  68 FILES SEARCHED...

   0 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L3   QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)

=> (alpha with facor with leader with sequence)
  15 FILES SEARCHED...
  25 FILES SEARCHED...
  27 FILES SEARCHED...
  36 FILES SEARCHED...
  54 FILES SEARCHED...
  71 FILES SEARCHED...
```

```
   0 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L4   QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE)

=> (alpha with factor with leader with sequence)
          3   FILE AGRICOLA
          7   FILE BIOBUSINESS
         30   FILE BIOSIS
         34   FILE BIOTECHABS
         34   FILE BIOTECHDS
  15 FILES SEARCHED...
          1   FILE CABA
          5   FILE CANCERLIT
         66   FILE CAPLUS
         85   FILE DGENE
  27 FILES SEARCHED...
          1   FILE DISSABS
          1   FILE DRUGU
  34 FILES SEARCHED...
          2   FILE GENBANK
  40 FILES SEARCHED...
         24   FILE IFIPAT
         16   FILE LIFESCI
         23   FILE MEDLINE
  54 FILES SEARCHED...
          3   FILE PROMT
         14   FILE TOXCENTER
        543   FILE USPATFULL
         43   FILE USPAT2
  71 FILES SEARCHED...
         12   FILE WPIDS
         12   FILE WPINDEX

  21 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L5   QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE)

=> (alpha with factor with leader with sequence) and  (ADH2 with promoter)
          1   FILE BIOSIS
          4   FILE BIOTECHABS
          4   FILE BIOTECHDS
  15 FILES SEARCHED...
          1   FILE CABA
          6   FILE CAPLUS
  26 FILES SEARCHED...
          3   FILE DGENE
  27 FILES SEARCHED...
  34 FILES SEARCHED...
  46 FILES SEARCHED...
          1   FILE MEDLINE
  54 FILES SEARCHED...
          1   FILE TOXCENTER
        399   FILE USPATFULL
         36   FILE USPAT2
  68 FILES SEARCHED...
          1   FILE WPIDS
          1   FILE WPINDEX

  12 FILES HAVE ONE OR MORE ANSWERS,   74 FILES SEARCHED IN STNINDEX

L6   QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)
```

```
=> (alpha with factor with leader with sequence) and  (ADH2 with promoter) and IL2
  14 FILES SEARCHED...
  18 FILES SEARCHED...
  27 FILES SEARCHED...
  34 FILES SEARCHED...
  51 FILES SEARCHED...
  54 FILES SEARCHED...
         8   FILE USPATFULL
         1   FILE USPAT2
  68 FILES SEARCHED...

   2 FILES HAVE ONE OR MORE ANSWERS,    74 FILES SEARCHED IN STNINDEX

L7   QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)
         AND IL2

=> d rank
F1           8   USPATFULL
F2           1   USPAT2


=> (alpha with factor with leader with sequence) and  (ADH2 with promoter)
         1   FILE BIOSIS
         4   FILE BIOTECHABS
         4   FILE BIOTECHDS
  15 FILES SEARCHED...
         1   FILE CABA
         6   FILE CAPLUS
  25 FILES SEARCHED...
         3   FILE DGENE
  27 FILES SEARCHED...
  34 FILES SEARCHED...
         1   FILE MEDLINE
  51 FILES SEARCHED...
  54 FILES SEARCHED...
         1   FILE TOXCENTER
       399   FILE USPATFULL
  67 FILES SEARCHED...
        36   FILE USPAT2
         1   FILE WPIDS
         1   FILE WPINDEX

  12 FILES HAVE ONE OR MORE ANSWERS,    74 FILES SEARCHED IN STNINDEX

L8   QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)


=> d rank
F1         399   USPATFULL
F2          36   USPAT2
F3           6   CAPLUS
F4           4   BIOTECHABS
F5           4   BIOTECHDS
F6           3   DGENE
F7           1   BIOSIS
F8           1   CABA
F9           1   MEDLINE
F10          1   TOXCENTER
F11          1   WPIDS
F12          1   WPINDEX


=> file caplus biotechabs biosis
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	67.85	68.06

FILE 'CAPLUS' ENTERED AT 18:56:44 ON 21 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 18:56:44 ON 21 NOV 2005
Copyright (c) 2005 The Thomson Corporation

=> file caplus biotechabs biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.30	69.36

FILE 'CAPLUS' ENTERED AT 18:56:47 ON 21 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHABS' TEMPORARILY UNAVAILABLE

FILE 'BIOSIS' ENTERED AT 18:56:47 ON 21 NOV 2005
Copyright (c) 2005 The Thomson Corporation
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> (alpha with factor with leader with sequence) and (ADH2 with promoter)
L9 7 (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)

=> d ab bib 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AB Provided is a method for producing physiol. active protein in high yields by controlling the redox potential of a fermentation A physiol. active protein such as IFN-α is characteristically produced in a high yield by using Saccharomyces cerevisiae DCO4 (KCTC0051BP) which is transformed with a plasmid having **ADH2/GAP promoter, alpha-factor leader sequence**, and genes of IFN-alpha, adjusting pH within the range of 4 to 8 for the fermentation and metal ions as oxidants or sulfur compound as reductants to keep redox potential value to be greater than 0 and smaller than 180.
AN 2004:856530 CAPLUS
DN 142:133164
TI Fermentation process for producing active proteins from recombinant Saccharomyces cerevisiae using redox potential control
IN Kwon, In Chan; Han, Kyu Boem
PA Lg Chemical Co., Ltd, S. Korea
SO Repub. Korea, No pp. given
CODEN: KRXXFC
DT Patent
LA Korean
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI KR 235462	B1	19991215	KR 1997-9188	19970318
PRAI KR 1997-9188		19970318		

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for controlling oxidation and reduction of physiol. active protein, which is produced from fermentation of recombinant microorganism, is provided by adding oxidant and reductant. Physiol. active protein, for example, IFN-α is produced in a high yield by using Saccharomyces cerevisiae DC04(KCTC 0051BP), which is transformed with a plasmid having **ADH2/GAP promoter, alpha-factor leader sequence** and genes of IFN-alpha, and adding 1-50 mM of sulfur compound as a reductant into medium wherein, the sulfur compound is selected from DTT(dithiothreitol), cysteine, or β-mercaptoethanol.

AN 2004:856529 CAPLUS

DN 142:133163

TI Redox potential control during Saccharomyces cerevisiae recombinant protein fermentations

IN Kwon, In Chan; Han, Kyu Boem

PA Lg Chemical Co., Ltd, S. Korea

SO Repub. Korea, No pp. given
CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 235461	B1	19991215	KR 1996-39670	19960913
PRAI	KR 1996-39670		19960913		

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for mass producing human interferon alpha(IFN-α) from the recombinant yeast is provided to improve a production yield and facilitate folding of the IFN-α. Human IFN α is mass produced from the recombinant yeast by incubating Saccharomyces cerevisiae DC04 transformed by the plasmid containing **ADH2/GAP promoter, alpha-factor leader sequence**, and the IFN-alpha gene in a medium containing metal ion at 25 to 30°, pH 4.5 to 5.0 under aerobic condition, adding a proper amount of glucose (avoiding accumulation in the medium), at the time of starting expression by exhaustion of glucose and ethanol. A 0.1 to 10 mM of metal ion is added into the medium to facilitate folding of the IFN-α; it contains copper, iron, zinc, manganese, molybdenum, and cobalt.

AN 2004:852101 CAPLUS

DN 142:79847

TI Method for mass producing human interferon alpha(IFN-α) from recombinant yeast

IN Han, Gyu Beom; Kwon, Seon Hun

PA Lg Chemical Co., Ltd., S. Korea

SO Repub. Korea, No pp. given
CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 177321	B1	19990401	KR 1996-26844	19960703
PRAI	KR 1996-26844		19960703		

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for producing human granulocyte colony stimulation factor(G-CSF) from recombinant yeast is provided. Recombinant yeast Saccharomyces cerevisiae DC04, which is transformed by a plasmid containing alc. dehydrogenase 2/glyceraldehyde-3-phosphate(**ADH2/GAP**) **promoter, .alpha.-factor leader sequence**, and the G-CSF gene in which 17th cysteine from 5' terminal is substituted with serine, is fed-batch fermented under conditions of 25 to 30 °C and pH 4.5-5.0 glucose is added into

reactor in order to maintain the yeast growth rate to 0.08 to 0.12 /h when ethanol the concentration is zero.

AN 2004:844141 CAPLUS
DN 142:54843
TI Human granulocyte-colony stimulating factor expression in recombinant Saccharomyces cerevisiae
IN Han, Kyu Sum; Kwon, Sun Hoon; Lee, Heung Yeup
PA Lg Chemical Ltd, S. Korea
SO Repub. Korea, No pp. given
CODEN: KRXXFC
DT Patent
LA Korean
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 154965	B1	19981015	KR 1996-75	19960105
PRAI KR 1996-75		19960105		

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AB Transmission-blocking vaccines based on sexual-stage surface antigens of P. falciparum may assist in the control of this lethal form of human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were secreted by S. cerevisiae, using the prepro-. **alpha.-factor leader sequence**.
Pfs25-28 fusion proteins were more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in mice that blocked oocyst development in Anopheles freeborni mosquitoes: complete inhibition of oocyst development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or Pfs28 alone. Increased antigen-specific IgG titers and highly significant lymphoproliferative stimulation by Pfs28-containing antigens suggest the presence of an immunodominant helper T-cell epitope in the Pfs28 portion of the fusion proteins. This epitope may be responsible for the enhanced humoral response to both Pfs25 and Pfs28 antigens. Protein production of the fusion protein was improved 12-fold by converting Pfs28 codons to yeast-preferred codons (TBV28), using a modified **ADH2 promoter** and incorporating a (Glu-Ala)2 repeat after the Kex2 cleavage site.
AN 1998:7805 CAPLUS
DN 128:113774
TI Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice
AU Gozar, Mary Margaret G.; Price, Virginia L.; Kaslow, David C.
CS Malaria Vaccines Section, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD, 20892-0425, USA
SO Infection and Immunity (1998), 66(1), 59-64
CODEN: INFIBR; ISSN: 0019-9567
PB American Society for Microbiology
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AB This article describes the construction of various alc. dehydrogenase 2 gene (**ADH2**) **promoter** plasmids for expression of heterologous proteins in yeast as well as for secretion into the culture medium. Plasmids YEpC-pADH2a, b, and d contain a polylinker following the **ADH2 promoter**. YEpC-PADH2a and YEpC-PADH2b contain the pUC13 polylinker in both orientations with unique restriction sites for SmaI, BamHI, and SalI. They do not have an ATG codon as does YEpC-PADH2d and therefore can be used for cloning and expression of intact genes. The yeast-Escherichia coli shuttle vector pαADH2 allows regulated

secretion of heterologous proteins via the **ADH2 promoter** fused to the .**alpha**.-**factor leader sequence**. The YIp5-derived integrating vectors pBC36 and pBC72 allow overprodn. of ADR1 which is required for pos. activation of the **ADH2 promoter**. The expression of several cDNAs encoding mouse and human granulocyte-macrophage colony-stimulating factor and human and bovine interleukin II was tested using vector pαADH2. The amount of heterologous protein secreted ranged from 5 to 70 μg/mL.

AN 1990:546651 CAPLUS
DN 113:146651
TI Expression of heterologous proteins in Saccharomyces cerevisiae using the **ADH2 promoter**
AU Price, Virginia L.; Taylor, Wayne E.; Clevenger, William; Worthington, Marlis; Young, Elton T.
CS Dep. Mol. Biol., Immunex Corp., Seattle, WA, 98101, USA
SO Methods in Enzymology (1990), 185(Gene Expression Technol.), 308-18
CODEN: MENZAU; ISSN: 0076-6879
DT Journal
LA English

L9 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AB Transmission-blocking vaccines based on sexual-stage surface antigens of Plasmodium falciparum may assist in the control of this lethal form of human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were secreted by Saccharomyces cerevisiae, using the prepro-**alpha-factor leader sequence**. Pfs25-28 fusion proteins were significantly more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in mice that blocked oocyst development in Anopheles freeborni mosquitoes: complete inhibition of oocyst development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or Pfs28 alone. Increased antigen-specific immunoglobulin G titers and highly significant lymphoproliferative stimulation by Pfs28-containing antigens suggest the presence of an immunodominant helper T-cell epitope in the Pfs28 portion of the fusion proteins. This epitope may be responsible for the enhanced humoral response to both Pfs25 and Pfs28 antigens. Protein production of the fusion protein was improved 12-fold by converting Pfs28 codons to yeast-preferred codons (TBV28), using a modified **ADH2 promoter** and incorporating a (Glu-Ala)2 repeat after the Kex2 cleavage site.

AN 1998:78406 BIOSIS
DN PREV199800078406
TI Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.
AU Gozar, Mary Margaret G.; Price, Virginia L.; Kaslow, David C. [Reprint author]
CS Malaria Vaccines Section, Lab. Parasitic Diseases, Natl. Inst. Health, Build. 4, Room B1-31, Bethesda, MD 20892-0425, USA
SO Infection and Immunity, (Jan., 1998) Vol. 66, No. 1, pp. 59-64. print.
CODEN: INFIBR. ISSN: 0019-9567.
DT Article
LA English
ED Entered STN: 24 Feb 1998
Last Updated on STN: 24 Feb 1998